Tamir Biotechnology, Inc.

Form 4 July 25, 2012

# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

**OMB APPROVAL** 

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or

Check this box

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* KENYON LAWRENCE A

2. Issuer Name and Ticker or Trading Symbol

Tamir Biotechnology, Inc. [ACEL]

5. Relationship of Reporting Person(s) to

(Check all applicable)

Issuer

below)

Director

(Last)

(First)

(Middle)

(Zip)

3. Date of Earliest Transaction

(Month/Day/Year)

07/23/2012

10% Owner X\_ Officer (give title Other (specify

C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, STE

(Street)

204

President, CEO and CFO

4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year) Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

**MONMOUTH** JUNCTION, NJ 08852

> (City) (State)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year)

Execution Date, if

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) 5. Amount of 6. Ownership Securities Form: Direct Beneficially Owned (I) Following (Instr. 4)

7. Nature of Indirect (D) or Indirect Beneficial Ownership

(Instr. 4)

(A) or

Transaction(s)

Reported

(Instr. 3 and 4) Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: Tamir Biotechnology, Inc. - Form 4

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | 5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |                                |
|---|---|---|---|--|---|--|--------------------|---|--------------------------------|
|   |   |   |   | Code V                                 | (A) (D  | ) Date<br>Exercisable                                    | Expiration<br>Date | Title   | Amount o<br>Number o<br>Shares |
| Common<br>Stock<br>(Right to<br>Buy) (1)            | \$ 0.04   | 07/23/2012                              |   | A                                      | 400,000   | (2)  | 07/23/2022         | Common<br>Stock   | 400,000                        |

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

KENYON LAWRENCE A C/O TAMIR BIOTECHNOLOGY, INC. 11 DEER PARK DRIVE, STE 204 MONMOUTH JUNCTION, NJ 08852

President, CEO and CFO

#### **Signatures**

/s/ Lawrence 07/25/2012 Kenyon

\*\*Signature of Date
Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Issued under the Company's 2004 Stock Incentive Plan and qualified under Rule 16b-3(d)
- (2) 25% of these options vest and become exercisable immediately, the grant date; 25% vest and become exercisable January 23, 2013; 25% vest and become exercisable July 23, 2013; and 25% vest and become exercisable January 23, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2